title: Correction of hyperinsulinemia in oligoovulatory women with clomiphene-resistant polycystic ovary syndrome: a review of therapeutic rationale and reproductive outcomes.
abstract: Polycystic ovary syndrome (PCOS) describes a convergence of chronic multisystem endocrine derangements, including irregular menses, hirsutism, obesity, hyperlipidemia, androgenization, large and cystic-appearing ovaries, insulin resistance and subfertility. Few PCOS patients exhibit all of these features, and often only one sign or symptom is evident. The sequelae of PCOS reach beyond reproductive health, as women affected with PCOS have increased relative risks for myocardial infarction, hypertension, ischemic heart disease, thromboembolic disease and diabetes. Although the adverse health consequences associated with PCOS are substantial, unfortunately most women are not aware of these risks. Indeed, in infertility practice such concerns are secondary as most patients are referred for treatment specifically to achieve a pregnancy. Impairments in insulin metabolism appear central to the physiologic cascade of PCOS, yet clomiphene therapy fails to remedy this defect. Several investigators have described satisfactory reproductive outcomes for PCOS patients treated with oral insulin-lowering agents. In this report, we outline a diagnostic and therapeutic approach for women with PCOS refractory to clomiphene with attention to the underlying insulin imbalance associated with impaired fertility.
authors.affiliation: Georgia Reproductive Specialists, Atlanta, GA, USA. dr.sills@ivf.com
authors.forename: E S
authors.initials: ES
authors.lastname: Sills
authors.forename: M
authors.initials: M
authors.lastname: Perloe
authors.forename: G D
authors.initials: GD
authors.lastname: Palermo
mesh_terms: D002996:Clomiphene / Q000627:therapeutic use*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D006946:Hyperinsulinism / Q000150:complications / Q000628:therapy*; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008687:Metformin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010060:Ovulation; D011085:Polycystic Ovary Syndrome / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D011247:Pregnancy; D012098:Reproduction
chemical_list: D007004:Hypoglycemic Agents; D002996:Clomiphene; D008687:Metformin